Emerging CAR-T Therapies in Large B-cell Lymphomas (LBCL): Highlights from ASH 2022 and Beyond : Episode 2

Treatment Strategies for Patients with R/R LBCL

Jan 24, 2023

By Manali Kamdar, MD
Matthew A. Lunning, DO, FACP

Experts provide their perspective on the treatment landscape for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

EP: 1.Overview of Large B-Cell Lymphoma (LBCL)

EP: 2.Treatment Strategies for Patients with R/R LBCL

Related Videos

Related Content

Cilta-cel Meets PFS End Point in Relapsed/Lenalidomide-Refractory Multiple Myeloma

January 27th 2023

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

Axi-cel Maintains PFS and ORR Benefit in 3-Year Follow-Up of ZUMA-5 in Indolent NHL

January 16th 2023

Cilta-cel Meets PFS End Point in Relapsed/Lenalidomide-Refractory Multiple Myeloma

January 27th 2023

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

Axi-cel Maintains PFS and ORR Benefit in 3-Year Follow-Up of ZUMA-5 in Indolent NHL

January 16th 2023

Cilta-cel Meets PFS End Point in Relapsed/Lenalidomide-Refractory Multiple Myeloma

January 27th 2023

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

Axi-cel Maintains PFS and ORR Benefit in 3-Year Follow-Up of ZUMA-5 in Indolent NHL

January 16th 2023

Related Content

Cilta-cel Meets PFS End Point in Relapsed/Lenalidomide-Refractory Multiple Myeloma

January 27th 2023

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

Axi-cel Maintains PFS and ORR Benefit in 3-Year Follow-Up of ZUMA-5 in Indolent NHL

January 16th 2023

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.